Investors & Funders in Health Tech
De-Risk Your Health Tech Portfolio with Patient-Proven Insights
Get faster product-market fit, long-term ROI and better outcomes backed by real patient stories and AI-driven validation.

Trusted by
The Risks You Can’t Ignore
Sky-High Failure Rates
Due Diligence Challenges
Burnout before Breakthrough
The Hidden Causes
Why Startups Really Fail
Why Due Diligence Falls Short
Why Energy Gets Wasted
Free Download
The Investor’s Playbook for Avoiding Health Tech Failures
Ensure the companies you fund are designed to last with frameworks that reduce failure risk and lead to scalable growth pathways.

Phicil-Itate Change
SEEDS Innovation Framework
Frequently Asked Questions
1. What exactly is the Innovation Readiness Assessment?
The Innovation Readiness Assessment is a proprietary due diligence tool that evaluates early-stage health tech startups across five critical domains: patient-market fit, health equity alignment, usability, regulatory foresight, and adoption readiness. It’s based on our SEEDS Innovation Framework and incorporates real patient narrative data from our Listen Phirst™Platform to highlight risks traditional diligence misses.
2. How does this help me make better investment decisions?
By surfacing gaps in clinical usability, patient trust, and systemic fit, we help you avoid costly misalignments that lead to product failure. You’ll get an objective lens on where a startup needs to pivot, validate further, or may not be ready for funding at all—before you commit capital.
3. What makes your methodology different from other ESG or diligence tools?
Unlike standard ESG checklists or retrospective data tools, we use multilingual, AI-analyzed patient narratives and blockchain-based consent systems to ensure authentic, inclusive, and real-time insights. Our SEEDS Innovation Framework is specifically designed to uncover risks related to equity, adoption, and scalability that other tools overlook.
4. Who is this best suited for—early-stage funds, growth-stage, or corporate investors?
Our tools work across stages but are especially valuable for early-stage (Pre-Seed to Series B) health tech investors, accelerators, and corporate venture arms that want to improve their diligence process, reduce risk, and meet ESG or impact investing mandates with real-world data.
Let’s De-Risk Your Health Tech Portfolio
Get a personalized Innovation Readiness Assessment that highlights red flags, ESG gaps,
and product-market misalignments – before you write the next check.



